Monte Rosa Therapeutics, Inc. Operating Leases, Rent Expense
Monte Rosa Therapeutics, Inc. (GLUE) reported Operating Leases, Rent Expense of $2.30 million for the 12-month period ending 2021-12-31, per its 10-K filed 2022-03-29.
Discontinued › Expense Statement › Operating Expenses
us-gaap:LeaseAndRentalExpense · last filed 2022-03-29
- Monte Rosa Therapeutics, Inc. operating leases, rent expense for fiscal 2021 was $2.30M, a 109.09% increase from fiscal 2020.
- Monte Rosa Therapeutics, Inc. operating leases, rent expense for fiscal 2020 was $1.10M.
| Period end | Operating Leases, Rent Expense 12 month |
|---|---|
| 2021-12-31 | $2.30M 10-K · filed 2022-03-29 |
| 2020-12-31 | $1.10M 10-K · filed 2022-03-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |